(BOSTON, Mass.) – Oct. 29, 2012 – Breast brachytherapy with a strut-based applicator had favorable toxicity rates and cosmetic outcomes, according to research delivered by 21st Century Oncology at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) – the largest radiation oncology society in the world.
The cutting-edge study at the ASTRO conference reported “excellent” or “good” cosmetic outcomes in more than 90 percent of patients, even those with the lumpectomy cavity in close proximity to the skin, who had strut-based brachytherapy. The analysis presented by Steven E. Finkelstein, M.D., Board Certified Radiation Oncologist based in Scottsdale, Ariz. and National Director of 21st Century Oncology’s research arm, the Translational Research Consortium (TRC), covered patients in three stages after treatment, including 146 breasts two years after brachytherapy.
The SAVI Collaborative Research Group, from which the data at ASTRO was drawn, was established to study clinical outcomes of APBI treatment with the SAVI device.
An ASTRO presentation by Robert L. Hong, M.D., also concluded that the strut-based applicator showed “excellent” local control of breast cancer recurrence and had favorably low rates of potential side effects of radiation therapy.
Strut-based brachytherapy is a method of delivering APBI, a shortened course of radiation therapy for early-stage breast cancer patients following lumpectomy surgery. Until the advent of the strut-based device, breast brachytherapy was delivered either with a balloon-based device or by the insertion of a multitude of catheters. Many patients are not eligible for treatment with the balloon device because the location of the lumpectomy cavity is in close proximity to healthy tissues such as the skin, heart, ribs, or lungs.
The strut-based applicator was developed to improve patient care and increase the number of women who are eligible for APBI by enabling physicians to sculpt radiation according to patient-specific anatomy. The reports presented at the ASTRO conference are among several clinical studies showing that by providing targeted radiation where it is needed most, the risks of toxicity and cosmetic side effects are reduced.
This form of radiation treatment is part of breast-conservation therapy, which includes lumpectomy– the surgical removal of the cancerous tissue within the breast plus tissue immediately around the tumor – followed by radiation. The breast-conserving approach is an alternative to mastectomy, which removes the entire breast and is often followed by breast reconstruction.
Video and text: Lower toxicities with strut-based brachytherapy: 4-year results
About 21st Century Oncology
21st Century Oncology is the largest global provider of Integrated Cancer Care services that strongly believes in fighting for patients like an army and caring for them like a family. Operating as one dream team in the crusade against cancer, the company employs or is affiliated with nearly 1,000 physicians globally to deliver the most advanced, integrated, and compassionate cancer care in personal and convenient settings. Headquartered in Fort Myers, FL, 21st Century Oncology operates 165 treatment centers, including 129 centers located in 15 U.S. states. In addition, the company operates 36 centers located in eight countries in Latin America. For more information, please visit https://www.21co.com/.
Cianna Medical, Inc. is a medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer. The company manufactures and markets the SAVI breast brachytherapy applicator, for the delivery of radiation after lumpectomy surgery. The applicator allows precise sculpting of the radiation dose, and is designed to make the benefits of accelerated partial breast irradiation available to a greater number of women.